NEW YORK – GATC Health and Liquid Biosciences said Wednesday that they are linking their bioinformatics platforms to accelerate biomarker and drug discovery for their pharmaceutical clients. The companies said that the partnership also will lower the cost of R&D and improve the safety and accuracy of clinical trials.
Liquid Biosciences, of Aliso Viejo, California, will provide its Emerge multiomic analysis platform to help uncover biological processes associated with specific diseases. Using its Multiomic Advanced Technology (MAT) system, Irvine, California-based GATC Health then will perform biological analysis for pharma firms to narrow their lists of potential compounds during preclinical development.
The MAT process includes whole-genome sequencing and analysis of genomes, proteomes, microbiomes, and other omic fields.
The collaboration will start with neurological diseases with "specific unmet needs," according to the companies.
"This partnership will provide a more complete picture of how a disease works and potential treatments," Liquid Biosciences CEO Patrick Lilley said in a statement. "By combining our Emerge mathematical evolution platform with GATC's comprehensive biological analysis, we can identify the right biology sooner and focus on a smaller set of potential compounds early in the preclinical development process, enabling pharma companies to develop drugs with more efficiency and a higher success rate."
John Stroh, GATC Health's interim CEO, added that the collaboration will help pharma companies advance precision medicine.